ASP2535 is a potent, selective, orally bioavailable, brain permeable and centrally-active glycine transporter-1 (GlyT1) inhibitor.ASP2535 can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease[1].
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor with an anti-inflammatory effect. LXW7 has a high binding affinity to αvβ3 integrin (IC50: 0.68 μM). It increases the phosphorylation of VEGFR-2 and activation of ERK1 2.